Macrocyclic peptide flexibility complicates lead optimisation.

In collaboration with Bristol Myers Squibb (BMS), we analysed the optimisation of the lead compound for PD-(L)1, which led to the clinical candidate BMT-174900. Template-free conformer generation, constrained by NMR-derived structural information, was used to identify bioactive macrocycle conformations for subsequent docking (PDB 6PV9) and ligand-strain estimation.

In this retrospective study, the approach ranked BMT-174900 among the six best-scoring compounds out of 72, suggesting that 80–90% of the analogues could have been eliminated from synthesis. 

This work: Jain AN, Brueckner, AC, Jorge, C, et al (2023)  J Comput Aided Mol Des 37 https://doi.org/10.1007/s10822-023-00524-2

This presentation was given on 11 November 2026 at Drug Discovery Europe Chemistry in Barcelona.

Meet the speaker

Mario Öeren

Principal Scientist

Mario applies his expertise in quantum chemistry and machine learning to support drug discovery research. His work involves developing machine learning and computational chemistry approaches for predicting drug metabolism and other properties relevant to drug discovery.  

With a PhD in Natural Sciences from TalTech, his academic work was focused on computational studies exploring infrared spectroscopy to determine the absolute configuration of flexible molecules and characterise macrocyclic host–guest complexes.

Connect on LinkedIn

Dr Mario Öeren, Principal Scientist, Optibrium